Depression pills that cause weight loss are a common concern for people starting or reviewing antidepressant treatment in the UK. While millions of people take antidepressants for depression and anxiety, their effects on body weight vary considerably depending on the specific drug, individual metabolism, and duration of use. Some antidepressants are broadly weight-neutral or associated with modest short-term weight loss, whilst others — such as mirtazapine and paroxetine — carry a higher risk of weight gain. Understanding these differences, alongside the primary goal of effectively treating depression, is essential for making informed, shared decisions with your GP or psychiatrist.

Antidepressants and Weight Changes: What the Evidence Shows

Antidepressants are among the most commonly prescribed medications in the UK, with millions of people taking them for depression, anxiety, and related conditions. One frequently discussed concern is their effect on body weight. The relationship between antidepressants and weight is complex and varies considerably depending on the specific drug, the individual's metabolism, lifestyle, and the duration of treatment.

A large UK primary care cohort study published in the BMJ (Gafoor et al., 2018) found that antidepressant use was associated with a small but measurable increased risk of weight gain over one to ten years of treatment, with the risk most pronounced after the first year of use. NICE guidance (NG222: Depression in Adults, 2022) acknowledges that weight change is a recognised side effect of several antidepressants and should be considered as part of shared decision-making and ongoing monitoring.

In the short term, some medications may cause initial weight loss — often due to reduced appetite as a side effect — before weight gradually increases with continued use. It is also important to recognise that depression itself can affect appetite and weight in both directions. Some people lose weight when depressed due to poor appetite, while others gain weight through comfort eating or reduced activity. When an antidepressant successfully treats depression, changes in appetite and energy levels may independently influence body weight. Research in this area is also subject to confounding by indication and illness severity, making it difficult to attribute weight changes solely to the medication. Understanding this distinction is essential before drawing conclusions about any particular drug's effect on weight.

Which Antidepressants Are Less Likely to Cause Weight Gain

Not all antidepressants carry the same risk of weight gain, and some are considered broadly weight-neutral or are associated with modest weight loss, at least in the short to medium term. Understanding these differences can help patients have more informed conversations with their prescribers. The British National Formulary (BNF) and NHS medicines information pages provide comparative adverse-effect profiles for individual drugs.

Selective serotonin reuptake inhibitors (SSRIs) — the most commonly prescribed class in the UK — have a mixed profile. Fluoxetine and sertraline are generally considered among the more weight-neutral SSRIs, particularly in the short term. Fluoxetine has been associated with modest initial weight loss in some patients, though this effect tends to diminish over time. Paroxetine, by contrast, carries a higher risk of weight gain compared with other SSRIs and is generally less preferred for this and other reasons, including a more pronounced discontinuation syndrome.

Certain antidepressants carry a notably higher risk of weight gain:

• Mirtazapine: Frequently associated with significant weight gain. Its Summary of Product Characteristics (SmPC) lists increased appetite and weight gain as very common side effects, partly attributable to its antihistaminergic properties.

• Tricyclic antidepressants (TCAs) such as amitriptyline: Also linked to weight gain. TCAs are generally not recommended as first-line treatment for depression due to their side-effect burden and significant risk of toxicity in overdose; at low doses they are more commonly used for conditions such as neuropathic pain.

• Paroxetine: As noted above, carries a higher weight-gain risk within the SSRI class.

Serotonin-noradrenaline reuptake inhibitors (SNRIs) such as venlafaxine and duloxetine are generally considered relatively weight-neutral, though individual responses vary. It is important to note that long-term weight trends may differ from short-term effects, and no antidepressant is officially licensed or recommended primarily as a weight-loss treatment. Any weight-related effects should be considered secondary to the primary goal of treating depression effectively.

Bupropion and Weight: What UK Patients Should Know

Bupropion is an antidepressant that works differently from SSRIs and SNRIs. It inhibits the reuptake of both dopamine and noradrenaline (an noradrenaline-dopamine reuptake inhibitor, NDRI), and has a well-documented association with weight neutrality or modest weight loss rather than weight gain. In clinical trials, bupropion has been shown to reduce appetite and promote modest weight loss in some individuals, which distinguishes it from many other antidepressants.

However, UK patients should be aware of an important regulatory distinction. In the UK, bupropion (marketed as Zyban) is licensed by the MHRA exclusively as an aid to smoking cessation — not as an antidepressant. It is not licensed in the UK for the treatment of depression, unlike in the United States, where it is widely prescribed under the brand name Wellbutrin for this purpose. Prescribing bupropion for depression in the UK would therefore constitute off-label use, which under GMC guidance requires clear clinical justification, documented informed consent, and a discussion of the absence of a UK licence for this indication.

The MHRA/EMC SmPC for Zyban lists several important contraindications that are particularly relevant in this context, including a current or previous seizure disorder, a current or prior diagnosis of an eating disorder such as bulimia nervosa or anorexia nervosa, and abrupt withdrawal from alcohol or benzodiazepines. These contraindications are clinically significant and must be assessed before any use of bupropion.

A combination product containing bupropion and naltrexone (Mysimba) is licensed in the UK for weight management in adults with obesity, as detailed in the EMA EPAR and UK SmPC, but this is not an antidepressant indication. Patients who have read about bupropion's antidepressant and weight-related effects online should discuss this openly with their GP or psychiatrist, who can explain the licensing context and explore whether alternative licensed treatments might better meet their individual needs. Self-medicating or sourcing unlicensed medications online carries significant safety risks and is strongly discouraged.

Risks of Prioritising Weight Loss When Choosing an Antidepressant

It is entirely understandable that patients living with depression may also have concerns about weight, particularly given the well-established links between obesity, mental health, and self-esteem. However, selecting or requesting an antidepressant primarily on the basis of its potential to cause weight loss carries meaningful clinical risks that are important to consider.

The most significant risk is inadequate treatment of depression. The primary goal of antidepressant therapy is to reduce depressive symptoms, improve functioning, and prevent relapse. If a medication that is less effective for a particular individual is chosen because of perceived weight benefits, the patient may experience prolonged or undertreated depression — which itself carries serious consequences, including increased risk of self-harm and suicide.

Additionally, the weight-related effects of antidepressants are highly variable and not reliably predictable for any given individual. A drug associated with weight loss in clinical trials may not produce the same effect in every patient. Other important considerations include:

• Side effect profile: Nausea, insomnia, sexual dysfunction, and cardiovascular effects vary between drugs.

• Drug interactions: Particularly relevant for patients on other medications.

• Comorbidities: Conditions such as epilepsy, eating disorders, or cardiac disease may contraindicate certain antidepressants. In people with a possible bipolar spectrum disorder, antidepressants can precipitate mania or hypomania; a careful history should be taken and specialist referral considered if this is suspected.

Patients with a history of eating disorders require particular caution, as focusing on weight-related drug effects may reinforce unhealthy thought patterns, and certain antidepressants (including bupropion) are contraindicated in this group.

Important — seek urgent help if you experience: new or worsening thoughts of suicide or self-harm, severe agitation or restlessness, symptoms that may suggest serotonin syndrome (such as confusion, rapid heart rate, muscle twitching, or high temperature), or signs of a serious allergic reaction. In these situations, contact your GP, call NHS 111, or in an emergency call 999 or go to your nearest A&E department. If you are in crisis and need to talk, the Samaritans are available 24 hours a day on 116 123 (free, no referral needed).

How to Discuss Weight Concerns With Your GP or Psychiatrist

Weight concerns are a legitimate and common reason why patients may feel reluctant to start antidepressants or may stop taking them without medical advice. Open communication with your GP or psychiatrist is essential, and healthcare professionals are trained to address these concerns sensitively and without judgement.

When attending an appointment, it can be helpful to:

• Be specific about your concerns — for example, whether you are worried about gaining weight, or whether you have already noticed changes since starting a medication.

• Mention any relevant history, such as previous experiences with antidepressants, a personal or family history of weight-related conditions, or a history of disordered eating.

• Ask about the evidence for weight effects of any proposed medication, and what monitoring will be in place.

Your GP or psychiatrist can discuss the relative weight profiles of different antidepressants and help weigh these against their effectiveness for your specific presentation. They may also refer you to a dietitian, or to NHS weight management services if appropriate, particularly if weight gain has already occurred.

It is important never to stop taking antidepressants abruptly without medical guidance, as this can cause discontinuation symptoms and risk a relapse of depression. If you are concerned about weight changes while on medication, contact your GP to review your treatment rather than stopping independently.

The NHS also offers NHS Talking Therapies for anxiety and depression (formerly known as IAPT), which provides evidence-based psychological therapies such as cognitive behavioural therapy (CBT). In many areas you can self-refer without a GP referral — visit the NHS website for details of your local service. Talking therapies may be used alongside or instead of medication depending on your circumstances and the severity of your depression.

If you are in crisis or experiencing thoughts of suicide or self-harm, please contact your GP urgently, call NHS 111, call 999 or go to A&E if you are in immediate danger, or contact the Samaritans on 116 123 at any time of day or night.

NICE Guidance on Choosing the Right Antidepressant for You

Current NICE guidance (NG222: Depression in Adults, 2022) provides a clear framework for the selection of antidepressants in the UK. The guidance recommends that the choice of antidepressant should be made collaboratively between the patient and clinician, taking into account the individual's symptoms, preferences, previous treatment response, potential side effects, and any comorbid conditions.

For most adults with moderate to severe depression, SSRIs are recommended as the first-line pharmacological treatment due to their favourable safety and tolerability profile compared to older antidepressants. NICE NG222 does not recommend choosing antidepressants on the basis of weight effects alone, but acknowledges that side effects — including weight changes — are a valid consideration in shared decision-making.

Key principles from NICE NG222 and NHS guidance include:

• Informed consent: Patients should be given clear information about the likely benefits and potential side effects of any antidepressant before starting treatment.

• Regular review: For most adults, treatment should be reviewed within two to four weeks of initiation. For people aged 18–25, or where there is a concern about suicide risk, a review within one week of starting treatment is recommended. Monitoring should include physical health parameters such as weight, particularly for medications with a known risk of metabolic effects.

• Stepped care and treatment matching: Antidepressants are one component of a broader treatment approach that may include psychological therapies, lifestyle interventions, and social support. NICE NG222 emphasises matching treatment choice to depression severity and individual patient preference.

Patients are encouraged to access reliable information through NHS sources such as the NHS website and the patient information leaflet provided with their medication. If you experience a suspected side effect — including unexpected weight changes — you can report this directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. This reporting contributes to ongoing post-marketing safety surveillance and helps protect other patients. Ultimately, the right antidepressant is the one that effectively treats your depression while being acceptable and tolerable to you as an individual.

Frequently Asked Questions